About AbbVie
AbbVies mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on peoples lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, womens health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Job Description and Title: Experiential Summer Intern, in vivo Technologies Group
Summary
The Biologics Generation Group at AbbVie is looking to host a Summer Intern (SI) for a minimum of 3+ months with an interest in antibody discovery and to assist in digitalizing historical hybridoma assets. S/he will participate in ongoing efforts to consolidate historical hybridoma assets and ensure accuracy of the hybridoma/cell line inventory as we transition from the Global Biologics Inventory System (GBIS) to FreezerPro (or another suitable inventory system). These efforts will significantly contribute towards the goal of digitalizing all historical hybridoma assets, thus reducing anticipated costs for storage of future hybridoma materials. The SI may also support the development of BRS dashboards to enable Hybridoma campaign timelines tracking and request progression. S/he will learn about target biology, in vivo antibody discovery and how to assess final data packages which includes project background, the hybridoma workflow stages, and recombinant data. SI support in these efforts will significantly alleviate the current workload of the In Vivo Antibody Discovery team.
Qualifications
Minimum Requirements:
* Must be enrolled in a Bachelors degree program with a major in Biochemistry, Biology, Neurobiology, Pre-Medicine or other related field
* Must be authorized to work in the U.S. on a permanent basis without requiring sponsorship
* Must be returning to university for at least one semester and graduating within one year post internship
* 3.0/4.9 GPA or equivalent
* Desired skills: Ability to thrive in a high-performance culture with excellent time management, decision-making, and organizational skills. Excellent oral/written communication skills with strong attention to detail and interpersonal skills. Ability to apply research findings, interpret and analyze results, develop, and implement a logical, and strategic plan of action.
Significant Work Activities
Continuous sitting for prolonged periods (more than 2 consecutive hours in an 8 hour day)
Travel
No
Job Type
Internship
Schedule
Full-time
Job Level Code
IC
Equal Employment Opportunity
At AbbVie, we value bringing together individuals from diverse backgrounds to develop new and innovative solutions for patients. As an equal opportunity employer we do not discriminate on the basis of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information gender identity or expression, sexual orientation, marital status, protected veteran status, or any other legally protected characteristic.
Chicago, IL
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia.
Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.